365 related articles for article (PubMed ID: 33199513)
1. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
2. Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.
Liu J; Blake SJ; Harjunpää H; Fairfax KA; Yong MC; Allen S; Kohrt HE; Takeda K; Smyth MJ; Teng MW
Cancer Res; 2016 Sep; 76(18):5288-301. PubMed ID: 27503925
[TBL] [Abstract][Full Text] [Related]
3. TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy.
Stone ML; Lee J; Herrera VM; Graham K; Lee JW; Huffman A; Coho H; Tooker E; Myers MI; Giannone M; Li Y; Buckingham TH; Long KB; Beatty GL
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34101617
[TBL] [Abstract][Full Text] [Related]
4. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
5. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
6. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
8. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
9. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
10. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
11. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
12. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
[TBL] [Abstract][Full Text] [Related]
13. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
Medina-Echeverz J; Ma C; Duffy AG; Eggert T; Hawk N; Kleiner DE; Korangy F; Greten TF
Cancer Immunol Res; 2015 May; 3(5):557-66. PubMed ID: 25637366
[TBL] [Abstract][Full Text] [Related]
14. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
15. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Sum E; Rapp M; Fröbel P; Le Clech M; Dürr H; Giusti AM; Perro M; Speziale D; Kunz L; Menietti E; Brünker P; Hopfer U; Lechmann M; Sobieniecki A; Appelt B; Adelfio R; Nicolini V; Freimoser-Grundschober A; Jordaan W; Labiano S; Weber F; Emrich T; Christen F; Essig B; Romero P; Trumpfheller C; Umaña P
Clin Cancer Res; 2021 Jul; 27(14):4036-4053. PubMed ID: 33771854
[TBL] [Abstract][Full Text] [Related]
17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
18. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.
Salomon R; Dahan R
Front Immunol; 2022; 13():940674. PubMed ID: 35911742
[TBL] [Abstract][Full Text] [Related]
19. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
Bello E; Cohen JV; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
[TBL] [Abstract][Full Text] [Related]
20. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity.
Alvarez M; Otano I; Minute L; Ochoa MC; Perez-Ruiz E; Melero I; Berraondo P
Cell Stress; 2019 Jun; 3(7):236-239. PubMed ID: 31309173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
